Cirrhosis Clinical Trials

26 studies are recruiting for cirrhosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

   This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy end…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute, Fairfax, Virginia

   Locations

   2 in total

   Run by

   Inova Health Care Services

   See if you can join NCT06007846 on ClinicalTrials.gov

2. Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

   A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Zydus US002, Indianapolis, Indiana

   Run by

   Zydus Therapeutics Inc.

   See if you can join NCT05045482 on ClinicalTrials.gov

3. Empagliflozin in Patients With Cirrhosis and Ascites

   A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05726032 on ClinicalTrials.gov

4. Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

   This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Dro…

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Giuseppe Cullaro, MD

   See if you can join NCT06937307 on ClinicalTrials.gov

5. InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

   This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The …

   Stage

   Not phased

   Ages

   Any age

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05463796 on ClinicalTrials.gov

6. Adverse Outcomes and Mortality in Liver Transplant

   Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT05477277 on ClinicalTrials.gov

7. Affect of Melatonin on Sleep and Cognition in Cirrhosis

   The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep,…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07046429 on ClinicalTrials.gov

8. Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

   Frailty and muscle health are important for patients with chronic liver disease. This study looks at the use of a digital prehabilitation app (HEAL-ME) plus creatine and whey protein combination supplementation on maintaining muscle health in patients with liver disease. The investigators anticipat…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07029243 on ClinicalTrials.gov

9. Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

   This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Zanzalintinib …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Run by

   Devalingam Mahalingam

   See if you can join NCT07042919 on ClinicalTrials.gov

10. Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

    The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in …

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama

    Locations

    34 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT05486572 on ClinicalTrials.gov

11. Bumetanide vs. Furosemide in Cirrhosis

    Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal vari…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Utah Hospital, Salt Lake City, Utah

    Run by

    Stacy Johnson

    See if you can join NCT06941415 on ClinicalTrials.gov

12. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    University of California San Diego NAFLD Research Center, La Jolla, California

    Locations

    13 in total

    Run by

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT05832229 on ClinicalTrials.gov

13. Microbiome Modulation With Prebiotics in PTSD and Cirrhosis

    Despite medical advancements, PTSD remains a major issue in Veterans1. Current treatment strategies have relatively poor adherence. In patients with PTSD and cirrhosis, there is greater cognitive impairment as well as changes in gut microbiome structure and function2,3. In addition, when there is c…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Hunter Holmes McGuire VA Medical Center, Richmond, Virginia

    Run by

    Hunter Holmes Mcguire Veteran Affairs Medical Center

    See if you can join NCT06464952 on ClinicalTrials.gov

14. CirrhosisRx CDS System

    The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients with cirrhosis.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California San Francisco Medical Center, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT05967273 on ClinicalTrials.gov

15. Copper Supplementation in Cirrhosis

    End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few …

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Washington Medical Center, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT07471542 on ClinicalTrials.gov

16. Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

    The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this stu…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06306963 on ClinicalTrials.gov

17. Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis

    Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Charleston Area Medical Center, Charleston, West Virginia

    Run by

    CAMC Health System

    See if you can join NCT06764966 on ClinicalTrials.gov

18. Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

    This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body a…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    2 in total

    Run by

    Mayo Clinic

    See if you can join NCT06425380 on ClinicalTrials.gov

19. Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting

    Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta super…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Cleveland Clinic Foundation, Cleveland, Ohio

    Run by

    The Cleveland Clinic

    See if you can join NCT03121404 on ClinicalTrials.gov

20. Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis

    To determine the rate and mechanisms of skeletal muscle protein synthesis and breakdown in cirrhotic patients by using multiple tracers and single muscle biopsies.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cleveland Clinic Foundation, Cleveland, Ohio

    Run by

    The Cleveland Clinic

    See if you can join NCT03225677 on ClinicalTrials.gov

21. Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

    Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Raymond Chung

    See if you can join NCT05028829 on ClinicalTrials.gov

22. Blood Collection Biorepository for Liver Disease Research

    The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.

    Stage

    Not phased

    Ages

    7 and older

    Site

    University at Buffalo, Buffalo General Medical Center, Buffalo, New York

    Run by

    State University of New York at Buffalo

    See if you can join NCT03025074 on ClinicalTrials.gov

23. HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

    This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT05205954 on ClinicalTrials.gov

24. LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

    The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specia…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05998330 on ClinicalTrials.gov

25. Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

    This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    834 Medical Oncology Dept, Univ Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Sofia, Sofia,

    Locations

    32 in total

    Run by

    Can-Fite BioPharma

    See if you can join NCT05201404 on ClinicalTrials.gov